Table 5.
Grade 3 and 4 laboratory abnormalities in the ANRS 130 Apollo trial
| Grade 3 or 4 abnormality | No. of events |
||
|---|---|---|---|
| Enfuvirtide group (n = 28) | Control group (n = 29) | Total (n = 57) | |
| Leukopenia/neutropenia (<2,000/750 cells/mm3) | 13 | 13 | 26 |
| ASAT, ALAT, PAL, bilirubin >5× ULNa | 11 | 4 | 15 |
| Related to antiretroviral drugs | 1 | 1 | |
| Triglycerides (≥8.6 mmol/liter) | 1 | 3 | 4 |
| Related to lopinavir | 1 | 1 | |
| Related to lopinavir and emtricitabine-tenofovir | 1 | 1 | |
| Phosphatemia (≤1.4 mg/dl) | 1 | 3 | 4 |
| Related to emtricitabine-tenofovir | 1 | 2 | 3 |
| Platelets (<50,000 cells/mm3) | 1 | 2 | 3 |
| Hemoglobin (<7 g/dl) | 1 | 1 | 2 |
| Proteinuria | 2 | 2 | |
| Related to emtricitabine-tenofovir | 1 | 1 | |
a
ASAT, aspartate transaminase; ALAT, alanine transaminase; PAL, alkaline phosphatase.